Purchase this article with an account.
Farnaz Memarzadeh, Rohit Varma, Le-Tien Lin, Jignesh G. Parikh, Laurie Dustin, Ana Alcaraz, Dean Eliott; Postoperative Use of Bevacizumab as an Antifibrotic Agent in Glaucoma Filtration Surgery in the Rabbit. Invest. Ophthalmol. Vis. Sci. 2009;50(7):3233-3237. doi: 10.1167/iovs.08-2441.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
purpose. To evaluate the efficacy of bevacizumab as an antifibrotic agent after trabeculectomy in rabbits.
methods. Forty-two rabbits underwent trabeculectomy and were randomly assigned to receive a postoperative course of seven subconjunctival injections of bevacizumab (1.25 mg, 25 mg/mL), 5-fluorouracil (5-FU; 5 mg, 50 mg/mL), or balanced salt solution (BSS; 0.1 mL, control). Bleb survival and characteristics were evaluated over a 30-day period. The animals were killed on postoperative day (PD)10, PD20, and PD30. Histology and immunohistochemistry of the surgical eyes was performed to evaluate and grade the amount of scarring and fibrosis in each group.
results. Bevacizumab significantly improved the outcome of filtration surgery in this model. Bevacizumab prolonged bleb survival compared with the 5-FU and control groups (16.0 ± 1.3 days vs. 6.9 ± 0.6 and 7.4 ± 0.85 days, respectively; P < 0.001). Bevacizumab-treated eyes had significantly larger and higher blebs than the control and 5-FU–treated groups (P < 0.05). Histologic analysis revealed that eyes treated with bevacizumab had significantly less postoperative scarring at the microscopic level at PD10 and PD20 (P = 0.009).
conclusions. Postoperative subconjunctival injection of bevacizumab is associated with improved trabeculectomy bleb survival in the rabbit model. Bevacizumab may be a useful agent for improving success and limiting scar tissue formation after trabeculectomy.
This PDF is available to Subscribers Only